查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1654632

全球心房颤动市场 - 2025 至 2033 年

Global Atrial Fibrillation Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球心房颤动市场规模达到 267.5 亿美元，预计到 2033 年将达到 637.9 亿美元，2025-2033 年预测期内的复合年增长率为 10.6%。

心房颤动是一种心臟上腔（称为心房）出现混乱电脉衝，导致心跳快速且不规律的疾病。这种不规律会导致心悸、头晕、疲劳和昏厥等症状。 AFib 在老年人和患有高血压、糖尿病和肥胖症等潜在健康问题的人中尤其常见。

全球心房颤动市场涵盖致力于心房颤动 (AFib) 的诊断、治疗和管理的经济部门，心房颤动是一种常见的心律不整类型，其特征是心律不整且通常心跳过快。 AFib 可能导致严重的併发症，包括增加中风和心臟衰竭的风险，因此有效的治疗至关重要。这些因素推动了全球心房颤动市场的扩张。

市场动态：

驱动因素与约束因素

医疗科技的进步

全球心房颤动 (AFib) 市场受到医疗技术进步的极大推动，医疗技术进步彻底改变了这种常见心律不整的诊断、治疗和管理。这些创新不仅改善了患者的治疗效果，而且还提高了程序效率并扩大了医疗服务提供者和患者的治疗选择。

这种创新技术利用电微脉衝在心臟组织中产生针对性病变，而不是传统的热或冷方法。 FARAPULSE 系统的最新批准体现了 PFA 如何为 AFib 治疗提​​供更精确的方法，透过有效隔离肺静脉并最大限度地减少併发症，实现更快、更安全的手术并提高成功率。 3D 映射系统等先进映射技术的整合彻底改变了导管消融程序。这些系统提供心臟电活动的即时可视化，使电生理学家能够准确识别和定位导致 AFib 的区域。

配备心电图功能的智慧手錶已成为持续心律监测的宝贵工具。 Apple Watch 等装置以及其他穿戴式装置可以即时追踪 AFib 发作，有助于早期诊断，而无需单纯依赖传统的心电图 (EKG)。人工智慧越来越多地被用于增强消融过程中的讯号分析，帮助临床医生更有效地识别心律不整的触发因素。透过分析先前 AFib 病例的复杂资料集，AI 可以帮助确定需要介入的区域，从而有可能提高治疗持续性 AFib 的成功率。

此外，该行业的主要参与者推出了创新产品，将推动全球心房颤动市场的成长。例如，2024年10月，强生医疗科技在欧洲各地的医院推出了VARIPULSE平台，代表了心房颤动(AFib)治疗领域的重大创新。此创新平台采用脉衝场消融 (PFA) 技术，为药物抵抗性阵发性心房颤动患者提供更安全、更有效的解决方案。

此外，2023 年 8 月，GE HealthCare 宣布推出用于心房颤动 (AFib) 的 CardioVisio，这是一款创新的数位工具，旨在帮助临床医生可视化与疾病进展相关的全面、纵向资料。这项创新工具整合了来自多个资料来源的信息，以增强临床决策并支持符合最新 AFib 指南的循证实践。所有这些因素都要求全球心房颤动市场的发展。

此外，对微创手术的需求不断增长，促进了全球心房颤动市场的扩张。

治疗费用高昂

全球心房颤动 (AFib) 市场面临重大挑战，主要是因为治疗这种常见心律不整的治疗费用高昂。这些费用可能会阻止患者寻求必要的护理并给医疗保健系统带来沉重的负担。以下是这些高昂的治疗费用如何影响 AFib 市场的解释。

根据美国国家生物技术资讯中心 (NCBI) 2024 年 2 月的研究资料，心房颤动 (AF) 患者的增量年化费用估计为每位患者 12,789 美元 +- 161,749 美元。医疗保健成本的大幅增加主要是由几个关键因素造成的，包括医疗保健就诊次数的增加、与 AF 相关的不良临床事件以及对特定 AF 相关干预措施的需求。

与没有心房颤动的患者相比，心房颤动患者通常需要更频繁的医疗就诊。这包括住院和门诊，这会导致更高的整体医疗费用。例如，患有持续性心房颤动 (PeAF) 的患者由于住院率增加和病情复杂，往往需要承担最高的费用。因此，上述因素可能会限制全球心房颤动市场的潜在成长。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动态

  • 影响因素
    • 驱动程式
      • 医疗科技的进步
    • 限制
      • 治疗费用高昂
    • 机会
    • 影响分析

第五章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 专利分析
  • 监管分析
  • SWOT 分析
  • 未满足的需求

第 6 章：按治疗类型

  • 药物治疗
    • 抗心律不整药物
    • 胺碘酮
    • 决奈达隆
    • 多非利特
    • 索他洛尔
    • 氟卡尼
    • 普罗帕酮
    • 地高辛
    • 抗凝血药物
    • 华法林
    • 达比加群
    • 利伐沙班
    • 阿哌沙班
    • 依度沙班
    • 非二氢吡啶类钙离子通道阻断剂
    • 地尔硫卓
    • 维拉帕米
    • β受体阻断剂
    • 美托洛尔
    • 卡维地洛
  • 其他的
  • 非药物治疗
    • 导管消融
    • 迷宫手术
    • 电復律
    • 其他的

第 7 章：按最终用户

  • 医院及专科诊所
  • 门诊手术中心
  • 其他的

第 8 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第九章：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 併购分析

第十章：公司简介

  • AdvaCare Pharma
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售量
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 合併与收购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT 分析
  • Sanofi
  • Pfizer Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Glenmark Pharmaceuticals Inc.
  • GSK plc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bayer AG
  • DAIICHI SANKYO COMPANY, LIMITED.
  • AstraZeneca
  • Johnson & Johnson
  • Boston Scientific Corporation
  • Medtronic
  • Abbott.

第 11 章：附录

简介目录
Product Code: PH446

The global atrial fibrillation market reached US$ 26.75 billion in 2024 and is expected to reach US$ 63.79 billion by 2033, growing at a CAGR of 10.6 % during the forecast period 2025-2033.

Atrial fibrillation is a condition in which the heart's upper chambers, known as the atria, experience chaotic electrical impulses, resulting in a fast and irregular heartbeat. This irregularity can cause symptoms such as palpitations, dizziness, fatigue, and fainting. AFib is particularly common among older adults and individuals with underlying health issues such as hypertension, diabetes, and obesity.

The global atrial fibrillation market encompasses the economic sector dedicated to the diagnosis, treatment, and management of atrial fibrillation (AFib), a prevalent type of arrhythmia characterized by irregular and often rapid heartbeats. AFib can lead to serious complications, including an increased risk of stroke and heart failure, making effective treatment essential. These factors have driven the global atrial fibrillation market expansion.

Market Dynamics: Drivers & Restraints

Advances in Medical Technology

The global atrial fibrillation (AFib) market is significantly driven by advances in medical technology, which have transformed the diagnosis, treatment, and management of this prevalent arrhythmia. These innovations not only enhance patient outcomes but also improve procedural efficiencies and expand treatment options for healthcare providers and patients alike.

This innovative technique utilizes micro pulses of electricity to create targeted lesions in cardiac tissue, as opposed to traditional heat or cold methods. The recent approval of the FARAPULSE system exemplifies how PFA provides a more precise approach to AFib treatment, leading to faster, safer procedures and improved success rates by effectively isolating the pulmonary veins and minimizing complications. The integration of advanced mapping technologies, such as 3D mapping systems, has revolutionized catheter ablation procedures. These systems offer real-time visualization of the heart's electrical activity, enabling electrophysiologists to accurately identify and target areas responsible for AFib.

Smartwatches equipped with ECG capabilities have emerged as valuable tools for continuous heart rhythm monitoring. Devices like the Apple Watch and other wearables allow for real-time tracking of AFib episodes, facilitating early diagnosis without relying solely on traditional electrocardiograms (EKGs). AI is increasingly being utilized to enhance signal analysis during ablation procedures, helping clinicians identify arrhythmia triggers more efficiently. By analyzing complex datasets from previous AFib cases, AI can assist in pinpointing areas that require intervention, potentially increasing the success rates of treating persistent AFib.

Furthermore, key players in the industry have innovative launches that would drive this global atrial fibrillation market growth. For instance, in October 2024, Johnson & Johnson MedTech introduced the VARIPULSE Platform in hospitals across Europe, representing a significant innovation in the treatment of atrial fibrillation (AFib). This innovative platform employs pulsed field ablation (PFA) technology, offering a safer and more effective solution for patients suffering from drug-refractory paroxysmal AFib.

Also, in August 2023, GE HealthCare announced the launch of CardioVisio for Atrial Fibrillation (AFib), an innovative digital tool aimed at assisting clinicians in visualizing comprehensive, longitudinal data related to disease progression. This innovative tool integrates information from multiple data sources to enhance clinical decision-making and support evidence-based practices aligned with the latest AFib guidelines. All these factors demand the global atrial fibrillation market.

Moreover, the growing demand for minimally invasive procedures contributes to the global atrial fibrillation market expansion.

High Costs of Treatment

The global atrial fibrillation (AFib) market faces significant challenges primarily due to the high costs of treatment associated with managing this common arrhythmia. These costs can deter patients from seeking necessary care and place a substantial burden on healthcare systems. Here's an explanation of how these high treatment costs impact the AFib market.

According to the National Center for Biotechnology Information (NCBI) research data in February 2024, the incremental annualized cost for patients with atrial fibrillation (AF) is estimated at $12,789 +- $161,749 per patient. This significant increase in healthcare costs is primarily driven by several key factors, including heightened rates of healthcare encounters, adverse clinical events associated with AF, and the need for specific AF-related interventions.

Patients with AF typically require more frequent healthcare visits compared to those without the condition. This includes both inpatient and outpatient visits, which lead to higher overall medical expenses. For instance, individuals with persistent atrial fibrillation (PeAF) often incur the highest costs due to increased hospitalization rates and the complexity of their condition. Thus, the above factors could be limiting the global atrial fibrillation market's potential growth.

Segment Analysis

The global atrial fibrillation market is segmented based on treatment type, end-user, and region.

Treatment Type:

The pharmacological treatment segment is expected to dominate the global atrial fibrillation market share

The pharmacological treatment segment holds a major portion of the global atrial fibrillation market share and is expected to continue to hold a significant portion of the global atrial fibrillation market share during the forecast period.

The pharmacological treatment segment for atrial fibrillation (AFib) is essential for managing this common heart condition and preventing its serious complications, particularly strokes. This segment is primarily divided into two main categories including anti-arrhythmic drugs and anticoagulant drugs. Anti-arrhythmic medications are designed to control heart rhythm and alleviate symptoms associated with AFib. They function by normalizing the heart's electrical activity or reducing the frequency of arrhythmias. These medications stabilize the heart's electrical activity by affecting ion channels involved in cardiac conduction, helping restore a normal rhythm and potentially reducing episodes of AFib.

Commonly used anti-arrhythmic drugs include amiodarone, sotalol, and flecainide. The choice of drug often depends on the patient's specific condition, including the type of AFib (paroxysmal, persistent, or permanent) and any underlying health issues.

Anticoagulants play a crucial role in preventing blood clots, which can lead to strokes-a significant risk associated with AFib. Warfarin has been the traditional anticoagulant for many years. While effective, it requires regular monitoring of blood levels (International Normalized Ratio, INR) to ensure therapeutic effectiveness and minimize the risk of bleeding. Many patients find managing warfarin challenging due to its complexity and dietary restrictions. More recently, NOACs such as dabigatran, rivaroxaban, apixaban, and edoxaban have emerged as preferred alternatives to warfarin. These newer agents do not require routine monitoring and have fewer dietary restrictions, making them more convenient for patients.

Furthermore, key players in the industry have innovative product launches and approvals that would drive this segment's growth in the global atrial fibrillation market. For instance, in December 2024, the FDA approved Rapiblyk (landiolol), a new medication specifically designed for the rapid management of irregular heartbeats in critically ill hospitalized patients experiencing severe supraventricular tachycardia (SVT), which includes conditions such as atrial fibrillation and atrial flutter. This approval represents a significant advancement in treatment options available for patients facing these potentially life-threatening arrhythmias. These factors have solidified the segment's position in the global atrial fibrillation market.

Geographical Analysis

North America is expected to hold a significant position in the global atrial fibrillation market share

North America holds a substantial position in the global atrial fibrillation market and is expected to hold most of the market share. The rising incidence of atrial fibrillation is a major driver of market growth. In the United States, Atrial fibrillation (AFib) is recognized as the most common form of irregular heartbeat, and it is projected that by 2030, around 12.1 million adults in the United States will be affected by this condition, with projections suggesting this number could reach 12.1 million by 2030. This escalating prevalence emphasizes the need for effective treatment options.

The aging demographic significantly contributes to the higher prevalence of AFib. As the population ages, there is an increased likelihood of developing cardiovascular conditions, leading to a greater demand for AFib treatments. Innovations in diagnostic and therapeutic technologies, such as catheter ablation and cryoablation procedures, are enhancing treatment options and attracting more patients toward specialized care. These advancements not only improve clinical outcomes but also increase patient preference for minimally invasive procedures.

Furthermore, a major number of key players' presence, well-advanced healthcare infrastructure, key initiatives & product approvals would drive this global atrial fibrillation market growth. For instance, in April 2024, the American Heart Association (AHA) initiated a new program aimed at involving pharmacists in the management of patients with atrial fibrillation (AFib), a prevalent heart condition affecting millions. This initiative is part of the AHA's broader Four Fs of Atrial Fibrillation campaign, which seeks to address specific patient health concerns that can impede effective anticoagulant therapy.

Also, in February 2023, Abbott announced two significant regulatory approvals as part of its expanding range of electrophysiology products in the global market. The TactiFlex Ablation Catheter, Sensor Enabled, recognized as the world's only ablation catheter with a flexible tip and contact force sensing technology, has received the CE Mark for use in treating patients with abnormal heart rhythms, including atrial fibrillation (AFib). Thus, the above factors are consolidating the region's position as a dominant force in the global atrial fibrillation market.

Asia Pacific is growing at the fastest pace in the global atrial fibrillation market share

Asia Pacific holds the fastest pace in the global atrial fibrillation market and is expected to hold most of the market share, fuelled by various factors that reflect the increasing prevalence of this condition and advancements in healthcare. Currently, more than 16 million people in the Asia Pacific region are affected by atrial fibrillation, with projections indicating this number could rise to 72 million by 2050. This escalating prevalence underscores the urgent need for effective treatment options.

The rising incidence of atrial fibrillation is a primary driver of market growth. The significant increase in AFib cases necessitates enhanced diagnostic and treatment options across the region. The aging demographic in Asia Pacific countries, particularly in nations like China and India, significantly contributes to the higher prevalence of AFib. As older adults are at a greater risk for cardiovascular diseases, this trend leads to increased demand for AFib treatments.

Innovations in diagnostic and therapeutic technologies, such as catheter ablation and cryoablation procedures, are enhancing treatment options for AFib patients. These advancements not only improve patient outcomes but also increase the preference for minimally invasive procedures. Increased healthcare spending in many Asia Pacific countries supports the adoption of advanced treatment options for AFib. This financial commitment allows for better access to medications, devices, and specialized care facilities.

Furthermore, key player's strategies such as partnerships & collaborations and innovative product launches & approvals would drive this global atrial fibrillation market growth. For instance, in May 2024, OMRON Healthcare India partnered with AliveCor India, a leader in personal electrocardiogram (ECG) technology, to enhance its cardiovascular health monitoring solutions, particularly focusing on atrial fibrillation (AFib). This collaboration is significant as it allows OMRON, which is primarily known for its blood pressure monitoring devices, to expand into the realm of AI-based handheld ECG technology.

Also, in May 2024, Medtronic announced that its PulseSelect pulsed field ablation (PFA) system has received regulatory approval in Japan, significantly expanding the availability of this innovative technology for treating patients with paroxysmal and persistent atrial fibrillation (AFib). Thus, the above factors are consolidating the region's position as the fastest-growing force in the global atrial fibrillation market.

Competitive Landscape

The major global players in the atrial fibrillation market include AdvaCare Pharma, Sanofi, Pfizer Inc. Teva Pharmaceuticals USA, Inc., Glenmark Pharmaceuticals Inc., GSK plc., Boehringer Ingelheim Pharmaceuticals, Inc., Bayer AG, DAIICHI SANKYO COMPANY, LIMITED., AstraZeneca, Johnson & Johnson, Boston Scientific Corporation, Medtronic, and Abbott. among others.

Key Developments

  • In November 2024, Johnson & Johnson MedTech announced that the U.S. Food and Drug Administration (FDA) has approved its VARIPULSE Platform to treat drug-refractory paroxysmal atrial fibrillation (AFib). This approval signifies a major advancement in cardiac arrhythmia treatment, particularly for patients who do not respond to standard drug therapies.
  • In May 2024, Saint Luke's Mid-America Heart Institute launched a comprehensive digital health program in partnership with Story Health to support patients diagnosed with atrial fibrillation (AFib) or those at risk of developing the condition. This initiative aims to enhance patient care by providing continuous support and engagement beyond traditional clinic visits.
  • In March 2024, Asheville's Mission Hospital announced that it is the first facility in North Carolina to implement a new ablation strategy for treating atrial fibrillation (AFib), the most common type of arrhythmia, which affects approximately seven million Americans. This innovative procedure utilizes the FARAPULSE PFA System, a state-of-the-art technology that enhances both the safety and effectiveness of AFib treatment.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global atrial fibrillation market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by End-User
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advances in Medical Technology
    • 4.1.2. Restraints
      • 4.1.2.1. High Costs of Treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Treatment Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 6.1.2. Market Attractiveness Index, By Treatment Type
  • 6.2. Pharmacological Treatment*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Anti-arrhythmic Drugs
    • 6.2.4. Amiodarone
    • 6.2.5. Dronedarone
    • 6.2.6. Dofetilide
    • 6.2.7. Sotalol
    • 6.2.8. Flecainide
    • 6.2.9. Propafenone
    • 6.2.10. Digoxin
    • 6.2.11. Anticoagulant Drugs
    • 6.2.12. Warfarin
    • 6.2.13. Dabigatran
    • 6.2.14. Rivaroxaban
    • 6.2.15. Apixaban
    • 6.2.16. Edoxaban
    • 6.2.17. Non-Dihydropyridine Calcium Channel Blockers
    • 6.2.18. Diltiazem
    • 6.2.19. Verapamil
    • 6.2.20. Beta-Blockers
    • 6.2.21. Metoprolol
    • 6.2.22. Carvedilol
  • 6.3. Others
  • 6.4. Non-Pharmacological Treatment
    • 6.4.1. Catheter Ablation
    • 6.4.2. Maze Surgery
    • 6.4.3. Electric Cardioversion
    • 6.4.4. Others

7. By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals & Specialty Clinics*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Ambulatory Surgical Centers
  • 7.4. Others

8. By Region

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.5.1. U.S.
      • 8.2.5.2. Canada
      • 8.2.5.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.5.1. Germany
      • 8.3.5.2. U.K.
      • 8.3.5.3. France
      • 8.3.5.4. Spain
      • 8.3.5.5. Italy
      • 8.3.5.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.5.1. Brazil
      • 8.4.5.2. Argentina
      • 8.4.5.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.5.1. China
      • 8.5.5.2. India
      • 8.5.5.3. Japan
      • 8.5.5.4. South Korea
      • 8.5.5.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape

  • 9.1. Competitive Scenario
  • 9.2. Market Positioning/Share Analysis
  • 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

  • 10.1. AdvaCare Pharma*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue's
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Sanofi
  • 10.3. Pfizer Inc.
  • 10.4. Teva Pharmaceuticals USA, Inc.
  • 10.5. Glenmark Pharmaceuticals Inc.
  • 10.6. GSK plc.
  • 10.7. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 10.8. Bayer AG
  • 10.9. DAIICHI SANKYO COMPANY, LIMITED.
  • 10.10. AstraZeneca
  • 10.11. Johnson & Johnson
  • 10.12. Boston Scientific Corporation
  • 10.13. Medtronic
  • 10.14. Abbott.

LIST NOT EXHAUSTIVE

11. Appendix

  • 11.1. About Us and Services
  • 11.2. Contact Us